Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating whether adding venetoclax to the standard combination of ibrutinib and obinutuzumab improves outcomes in untreated older adults wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)
• Venclyxto (Venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-02